It has been revealed that cell viability loss can be reversed by JNK inhibitor but not p38 inhibitor, indicating that JNK activation results in cell death in breast cancer, CML and cervical cancer (21, 39, 56). This evidence concerns the gene MAPK8 and chronic myelogenous leukemia, BCR-ABL1 positive.